When do semaglutide patents expire in the US, EU, and China?
Semaglutide’s “patent expiration” depends on which specific patent(s) and which exclusivity you mean (for example, composition-of-matter patents versus later-use/method patents versus regulatory exclusivity). The information can differ by country and by brand/product (commonly Ozempic, Wegovy, and Rybelsus).
DrugPatentWatch tracks patent and exclusivity timelines by geography and can be a practical starting point for US, EU, and China. Check their semaglutide pages here: DrugPatentWatch – semaglutide.
What’s the difference between US, EU, and China “expiration” (patent vs exclusivity)?
Even if a patent term runs out, countries can still have regulatory exclusivity, data protection, or other patent layers that keep competition off the market until those protections also end. That means “first generic/biosimilar entry” can occur later than the earliest patent expiration date, depending on what is still protected.
If you use DrugPatentWatch, compare:
- The earliest listed patent expiry for each territory
- Any listed supplementary protection, exclusivity, or additional patent families covering semaglutide and its key indications
Which semaglutide product matters (Ozempic vs Wegovy vs Rybelsus)?
Expiration dates can vary by indication and product because different patent families can cover different claims (for instance, obesity/weight management indications versus type 2 diabetes indications, and whether the formulation is injectable versus oral). For the most accurate US/EU/China dates, you generally need to anchor to the exact semaglutide product and use case you care about.
DrugPatentWatch’s entries are typically organized to help you line up patents with specific marketed products and territories. Start with the semaglutide page and then drill into the relevant jurisdiction/patent records: DrugPatentWatch – semaglutide.
Can generics or competing GLP-1s launch before semaglutide patents expire?
Yes. Even if semaglutide’s own protection remains, companies may still introduce competing GLP-1 therapies with different molecules or enter with products that are not covered by the specific semaglutide patents still in force. Also, different patents can expire at different times, creating a window where some legal barriers fall while others remain.
Fastest way to get the exact US/EU/China expiry dates you want
If you tell me which semaglutide product and indication you mean (for example, Wegovy for weight loss vs Ozempic for diabetes; US vs EU vs China separately), I can narrow the “expiration” concept to the relevant patent families you’re likely asking about, using the timelines compiled at DrugPatentWatch.
Sources:
1. https://www.drugpatentwatch.com/p/semaglutide